By Christian Cobaugh, CEO and Founder Monoclonal antibodies (mAbs) have emerged as one of the most successful drug products and biochemical reagents of the 21st century, owing to their broad range of activities, target specificity, and ease of manufacturing. There…
We cannot believe it has been 2 years. Happy Birthday Vernal Biosciences! See how Vernal has grown since 2021 and expanded its capabilities for mRNA, LNP, and GMP!
By Julia Sakamoto, Marketing Specialist The development of mRNA vaccines has been ongoing since the late 80s, but it wasn’t until the COVID-19 pandemic that this technology became widely recognized. Instead of using an antigen to trigger the body’s immune…
Vernal’s mission has always been to democratize access to mRNA. One of the ways we are achieving this is expanding our capabilities in mRNA process and development so that we can provide GMP for clinical use cases. Take a look…
Didn’t have a chance to attend the 2022 mRNA Health Conference and talk about mRNA manufacturing needs for your projects? Download a copy of our poster regarding the “Design, formulation, and manufacturing of LNP-mRNA for clinically relevant applications” authored by…